About Us

SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Thirteenth Five-Year Plan Period.

 

Product Pipeline


sm03hover11-11

Core Product


Anti-CD22


First-in-Target

sn11hover1-1

NCE
Drug Candidate

BTK Inhibitor


Third-Generation

sm17hover11-11

Biologic Candidates


Humanized Anti-IL17BR


First-in-Class and First-in-Target

sm09hover1-1





Humanized Anti-CD20

over11-11





Humanized Anti-CD22

tn02hover1-1





Humanized Ab


What's News



Our Office